tosposertib

{
  "id": "MLC-T-ONC-017276",
  "term": "tosposertib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of transforming growth factor-beta (TGFb), with potential antineoplastic and anti-fibrotic activities. Upon oral administration, tosposertib specifically targets, binds to and inhibits TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This abrogates TGFb-mediated fibrosis and immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often upregulated and activated in fibrotic diseases and deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.",
  "synonyms": [
    "TGF-beta inhibitor TU2218",
    "TGFb inhibitor TU2218",
    "TGFbeta antagonist TU2218",
    "TGFbeta inhibitor TU2218"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tosposertib/"
}